Boehringer Ingelheim establishes joint venture to combat antimicrobial resistance

Boehringer Ingelheim, Evotec SE, a life sciences company, and bioMérieux, a global leader in in vitro diagnostics, are working together to develop practical diagnostics to combat antimicrobial resistance (AMR) as well as to create the next generation of antibiotics. announced the establishment of a joint venture.

The resulting company, Aurobac Therapeutics SAS, will combine the best competencies of the three founding companies towards developing new precision medicine approaches, from diagnosis to treatment. The ambition is to succeed in fighting AMR, a major public health threat. Routine surgeries such as caesarean sections and total hip replacements can be life-threatening, and complications from diabetes and common ailments such as injuries and cuts are difficult to manage as patients become more resistant to antibiotics. Become.

Aurovac will work to transform strategies related to antibiotic treatment regimens. At present, it relies heavily on an empirical approach using broad-spectrum, unfocused medicines. The goal is to turn this into a precise approach, using highly effective and targeted new modalities, combined with rapid, actionable diagnostics to rapidly identify pathogens and their resistance patterns, To be supported by the new economic model.

Three partners in the fight against AMR

Boehringer Ingelheim’s participation in Aurovac is part of a broader so-called anti-pandemic initiative that includes Boehringer Ingelheim’s €50 million investment in the AMR Action Fund. The Boehringer Ingelheim Venture Fund has committed to investing in up to 12 of his AMR-infected companies.

With over 55 years of diagnostic expertise, bioMérieux focuses more than 75% of its R&D budget on antimicrobial resistance. Additionally, 80% of sales are related to the fight against AMR through complete diagnostic solutions that facilitate antibiotic therapy decision-making, including initiation, optimization and discontinuation of antibiotics.

Evotec has built the world’s leading platform for tackling infectious diseases. With a strong anti-infective discovery team of over 200 people, the company has proven experience with multiple pathogen classes. In addition to its Pre-Competitive Pandemic Preparedness and Rapid Response Technology Platform (PRROTECT), Evotec is leveraging its infectious disease capabilities with many industry, academic and non-profit partners, and across various networks such as the AMR Accelerator. I am active. Part of the EU’s Innovative Medicines Initiative (IMI).

Werner Lanthaler, CEO of Evotec, said: Together with his partners Boehringer Ingelheim and bioMérieux, he looks forward to launching Aurovac and combining their complementary strengths. By leveraging Evotec’s multidisciplinary approach to infectious diseases, Aurobac is confident that he will be able to make the progress needed to tackle the global challenge of AMR. ”

bioMérieux Chairman and CEO, Alexandre Mérieux, said: We offer the most comprehensive integrated diagnostic solutions to support appropriate antibiotic use (antibiotic management). Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, that provide fast, reliable and actionable results. This participation in Aurovac is fully consistent with bioMérieux’s full commitment to maintaining the efficacy of antibiotics for future generations. ”

Boehringer Ingelheim establishes joint venture to combat antimicrobial resistance

Source link Boehringer Ingelheim establishes joint venture to combat antimicrobial resistance

Related Articles

Back to top button